27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
A recent randomized trial demonstrated clear cerebrospinal-fluid DHA target engagement without detectable improvement in cognition or brain volume over 24 months. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
BAN2401 was well-tolerated across all doses. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. 5 key findings →
Design: clinical trial Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Our study highlights factors associated with the development of CMHs in individuals with DIAD. 5 key findings →
Design: cross-sectional Participants: 310 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age was the strongest risk factor for progression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
APOE -ε4 allele[s] is a risk factor for Alzheimer's disease (AD) and Amyloid-Related Imaging Abnormalities (ARIA) in anti-amyloid beta therapy, and is also associated with cerebrovascular risk factors such as hyperlipidemia or atherosclerosis. 4 key findings →
Participants: 6,313 Evidence: high
Full summary, score breakdown and related studies → Original source
BackgroundAlzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages. 4 key findings →
Design: clinical trial Participants: 763 Evidence: low
Full summary, score breakdown and related studies → Original source
ABSTRACTBackground:This systematic overview reports findings from systematic reviews of randomized controlled trials of pharmacological and non-pharmacological interventions for behavioural and psychological symptoms of dementia (BPSD). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
All ChEIs significantly improved cognitive and neuropsychiatric measures. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
OF THE FIELD: Alzheimer's disease (AD) is the most frequent, age-related neurodegenerative disorder and is characterized by progressive deterioration of cognition and global functioning. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
14 studies were identified that matched inclusion criteria. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
PRT may have a small beneficial effect on cognitive function in SVCI. 5 key findings →
Design: RCT Participants: 91 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease. 1 key finding →
Design: open-label trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. 3 key findings →
Participants: 228 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The mean (SD) age in the CA group was 72.2(7.5) years (range, 60-80 years), and in the placebo group it was 71.7 (7.4) years(range, 60-80 years). 3 key findings →
Participants: 261 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
All treatment groups showed improvement in measures of psychosis without significant differences between them when planned comparisons were performed. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Treatment also increased REM sleep duration and reduced ADAS-cog scores. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) often represents an early form of Alzheimer disease (AD). 2 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Overall, 318 patients with AD completed BPST with an improvement of 5.6 points on the total Cohen-Mansfield Agitation Inventory (CMAI; mean [SD], 63.3 [16.0] to 57.7 [18.4], t = 4.8, df = 317, p 95% of patients. 2 key findings →
Design: randomized controlled trial Participants: 318 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →